Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Key Takeaways The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents.